{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:07:57Z","timestamp":1792843677952,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.esmoop.2024.103636","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T06:51:48Z","timestamp":1720853508000},"page":"103636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["A first-in-human phase I study of a novel MDM2\/p53 inhibitor alrizomadlin in advanced solid tumors"],"prefix":"10.1016","volume":"9","author":[{"given":"X.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103636_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2024.103636_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.esmoop.2024.103636_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.esmoop.2024.103636_bib4","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","article-title":"The p53 pathway: positive and negative feedback loops","volume":"24","author":"Harris","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2024.103636_bib5","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026336","article-title":"The role of MDM2 amplification and overexpression in tumorigenesis","volume":"6","author":"Oliner","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.esmoop.2024.103636_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","article-title":"p53: 800 million years of evolution and 40 years of discovery","volume":"20","author":"Levine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2024.103636_bib7","first-page":"1001","article-title":"The MDM2-p53 interaction","volume":"1","author":"Moll","year":"2003","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103636_bib8","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","article-title":"Targeting the MDM2-p53 interaction for cancer therapy","volume":"14","author":"Shangary","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103636_bib9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41374-019-0263-4","article-title":"Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology","volume":"99","author":"Kim","year":"2019","journal-title":"Lab Invest"},{"key":"10.1016\/j.esmoop.2024.103636_bib10","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2024.103636_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2024.103636_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1309\/AJCPLYU89XHSNHQO","article-title":"MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors","volume":"141","author":"Ware","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.esmoop.2024.103636_bib13","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/acs.jmedchem.6b01665","article-title":"2.2.2]octane-1-carboxylic acid (AA-115\/APG-115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development","volume":"60","author":"Aguilar","year":"2017","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.esmoop.2024.103636_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41420-021-00465-5","article-title":"MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models","volume":"7","author":"Fang","year":"2021","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.esmoop.2024.103636_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s40425-019-0750-6","article-title":"MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment","volume":"7","author":"Fang","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2024.103636_bib16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41590-021-00888-3","article-title":"The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity","volume":"22","author":"Zhou","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.esmoop.2024.103636_bib17","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1200\/JCO.2022.40.16_suppl.9517","article-title":"Newly updated activity results of alrizomadlin (APG-115), a novel MDM2\/p53 inhibitor, plus pembrolizumab: phase 2 study in adults and children with various solid tumors","volume":"40","author":"McKean","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103636_bib18","doi-asserted-by":"crossref","first-page":"9559","DOI":"10.1200\/JCO.2023.41.16_suppl.9559","article-title":"A\u00a0phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs","volume":"41","author":"Shaheen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103636_bib19","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.esmoop.2024.103636_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2017.02.005","article-title":"A\u00a0phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours","volume":"76","author":"de Jonge","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103636_bib21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.2016.70.7117","article-title":"Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors","volume":"35","author":"Wagner","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103636_bib22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103636_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106222","article-title":"Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: a systematic review of the literature","volume":"86","author":"Pi","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.esmoop.2024.103636_bib24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103636_bib25","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.22.01285","article-title":"A\u00a0first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas","volume":"41","author":"Gounder","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103636_bib26","doi-asserted-by":"crossref","first-page":"31980","DOI":"10.18632\/oncotarget.7881","article-title":"P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis","volume":"7","author":"Mahfoudhi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2024.103636_bib27","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood-2012-05-356014","article-title":"The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans","volume":"120","author":"Pant","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2024.103636_bib28","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.3390\/cancers15143560","article-title":"The development of p53-targeted therapies for human cancers","volume":"15","author":"Lu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2024.103636_bib29","first-page":"1023","article-title":"Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation","volume":"2","author":"Yang","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2024.103636_bib30","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdr485","article-title":"Advanced well-differentiated\/dedifferentiated liposarcomas: role of chemotherapy and survival","volume":"23","author":"Italiano","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103636_bib31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000500608","article-title":"Retrospective analysis of patients with advanced liposarcoma in a tertiary referral center","volume":"42","author":"Langmans","year":"2019","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.esmoop.2024.103636_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/14737140.2014.869173","article-title":"Current management options for liposarcoma and challenges for the future","volume":"14","author":"Koll\u00e1r","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.esmoop.2024.103636_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2017.74.9598","article-title":"Clinical and molecular spectrum of liposarcoma","volume":"36","author":"Lee","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103636_bib34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10637-019-00840-1","article-title":"Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma","volume":"38","author":"Gluck","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.esmoop.2024.103636_bib35","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","article-title":"The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study","volume":"13","author":"LoRusso","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.103636_bib36","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1158\/0008-5472.CAN-20-0189","article-title":"Inhibition of MDM2 promotes antitumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103636_bib37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41420-020-0292-1","article-title":"AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing","volume":"6","author":"Sahin","year":"2020","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.esmoop.2024.103636_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13046-018-0765-8","article-title":"A\u00a0novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma","volume":"37","author":"Yi","year":"2018","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103636_bib39","article-title":"Abstract 307: Targeting BCL-2 and BCL-xL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103636_bib40","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/1538-7445.AM2023-1632","article-title":"Abstract 1632: MDM2 inhibitor alrizomadlin (APG-115) promotes antitumor activity of mitogen-activated protein kinase (MAPK) inhibitors in uveal melanoma","volume":"83","author":"Wang","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103636_bib41","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-3223","article-title":"Abstract 3223: Embryonic ectoderm development (EED) inhibitor APG-5918 (EEDi-5273) and MDM2 inhibitor alrizomadlin (APG-115) synergistically inhibit tumor growth in preclinical models of prostate cancer (PCa)","volume":"84","author":"Yin","year":"2024","journal-title":"Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:06:35Z","timestamp":1737331595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2059702924014054"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103636","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human phase I study of a novel MDM2\/p53 inhibitor alrizomadlin in advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103636"}}